Ocugen to Share Gene Therapy Advances at Upcoming May Conferences: What it Means for the IRD Community
For individuals and families living with inherited retinal diseases (IRDs), news of advancements in gene therapy offers a beacon of hope. Ocugen, Inc., a biotechnology company focused on gene therapies for blindness diseases, recently announced its participation in scientific and investor conferences in May 2026. These events provide a platform for the company to share updates on its innovative modifier gene therapy platform, which aims to address a broad range of IRDs, including retinitis pigmentosa and Stargardt disease.
Key Information from Ocugen's Announcement
Ocugen is scheduled to present at two significant events in May 2026: the Retina World Congress and the Stifel 2026 Virtual Ophthalmology Forum.
- Retina World Congress: Ocugen will present on Thursday, May 14, 2026, from 10:31 a.m. to 11:10 a.m. EDT, during the Inherited and Rare Retinal Diseases Session.
- Stifel 2026 Virtual Ophthalmology Forum: The company's presentation is set for Tuesday, May 26, 2026, from 10:30 a.m. to 10:55 a.m. EDT. This event will be virtual, with a webcast available on Ocugen's investor relations website, and a replay accessible for 30 days following the event.
These presentations will focus on Ocugen's